Sinopharm Group Overview
- Year Founded
-
2003
- Status
-
Public
- Employees
-
90,447
- Stock Symbol
-
01099
- Investments
-
14
- Share Price
-
$2.14
- (As of Friday Closing)
Sinopharm Group General Information
Description
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2024. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
Contact Information
Website
www.ir.sinopharmgroup.com.cnCorporate Office
- 9/F, The Center, 99 Queen's Road, Central
- Hong Kong, 200051
- China
Corporate Office
- 9/F, The Center, 99 Queen's Road, Central
- Hong Kong, 200051
- China
Sinopharm Group Stock Performance
As of 20-Nov-2026, Sinopharm Group’s stock price is $2.14. Its current market cap is $6.69B with 3.12B shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.14 | $2.16 | $1.85 - $2.86 | $6.69B | 3.12B | 5.6M | $0.32 |
Sinopharm Group Financials Summary
As of 30-Jun-2026, Sinopharm Group has a trailing 12-month revenue of $81.7B.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 16,597,232 | 23,078,039 | 23,099,863 | 25,194,408 |
| Revenue | 81,734,323 | 79,980,849 | 81,459,297 | 84,322,217 |
| EBITDA | 2,889,115 | 2,904,686 | 2,905,968 | 3,696,968 |
| Net Income | 1,013,694 | 994,963 | 982,471 | 1,279,705 |
| Total Assets | 59,524,392 | 55,792,190 | 53,811,762 | 54,086,116 |
| Total Debt | 11,968,311 | 10,141,985 | 10,463,711 | 10,408,522 |
Sinopharm Group Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Sinopharm Group Comparisons
Industry
Financing
Details
Sinopharm Group Competitors (1)
One of Sinopharm Group’s competitors is Sinovac Biotech, a Corporation company based in Beijing, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Sinovac Biotech | Corporation | Beijing, China |
Sinopharm Group Signals
Sinopharm Group Investments & Acquisitions (14)
Sinopharm Group’s most recent deal was a Early Stage VC with Jinju Biomedicine. The deal was made on 19-Nov-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Jinju Biomedicine | 19-Nov-2025 | Early Stage VC | Biotechnology | ||
| Hayat Biotech | 08-Apr-2025 | Joint Venture | Biotechnology | ||
| Joint Venture (Elekta / Sinopharm Group) | 07-Sep-2023 | Joint Venture | Medical Supplies | ||
| Hayat-Vax Vaccine Manufacturing (G42 / Sinopharm CNBG) | 28-Mar-2021 | Joint Venture | Pharmaceuticals | ||
| HY Medical | 16-Nov-2020 | Later Stage VC | Decision/Risk Analysis |
Sinopharm Group ESG
Risk Overview
Risk Rating
Updated November, 17, 2026
15.9 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Healthcare
Industry
of 590
Rank
Percentile
Medical Distribution
Subindustry
of 42
Rank
Percentile
Sinopharm Group Exits (2)
Sinopharm Group’s most recent exit was on 01-May-2019 from GemPharmatech. The exit was categorized as with 2 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| GemPharmatech | 01-May-2019 | Completed |
|
||
| Jienuo Medical Management Group | 20-Feb-2019 | Secondary Transaction - Private | Completed |
Sinopharm Group Affiliates
Subsidiaries (4)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Sinopharm Capital | Shanghai, China | 2012 | |
| China National Medicines Corporation | Beijing, China | 1999 | |
| China National Pharmaceutical Investment | Beijing, China | 1964 | |
| Sinopharm Medical Equipment | Beijing, China | 1962 |
Sinopharm Group FAQs
-
When was Sinopharm Group founded?
Sinopharm Group was founded in 2003.
-
Where is Sinopharm Group headquartered?
Sinopharm Group is headquartered in Hong Kong, China.
-
What is the size of Sinopharm Group?
Sinopharm Group has 90,447 total employees.
-
What industry is Sinopharm Group in?
Sinopharm Group’s primary industry is Pharmaceuticals.
-
Is Sinopharm Group a private or public company?
Sinopharm Group is a Public company.
-
What is Sinopharm Group’s stock symbol?
The ticker symbol for Sinopharm Group is 01099.
-
What is the current stock price of Sinopharm Group?
As of 20-Nov-2026 the stock price of Sinopharm Group is $2.14.
-
What is the current market cap of Sinopharm Group?
The current market capitalization of Sinopharm Group is $6.69B.
-
What is Sinopharm Group’s current revenue?
The trailing twelve month revenue for Sinopharm Group is $81.7B.
-
Who are Sinopharm Group’s competitors?
Sinovac Biotech is a competitor of Sinopharm Group.
-
What is Sinopharm Group’s annual earnings per share (EPS)?
Sinopharm Group’s EPS for 12 months was $0.32.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process